6 news items
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
NRIX
16 Jun 24
give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
ADIL
ALLR
APLD
12 Apr 24
% to $0.2898 in pre-market trading. Draganfly will showcase cutting-edge drone technologies at XPONENTIAL 2024 in San Diego.
Assure Holdings
Nurix Therapeutics Announces Proposed Public Offering
NRIX
11 Apr 24
will be offered and sold by Nurix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
NRIX
9 Apr 24
believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
NRIX
2 Apr 24
no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties
u3ivzxc15ew5l8ffhjkimonqvv0n7a7c18uk9oydd5rl6m6kb428fzw483
NRIX
25 Mar 24
reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements
- Prev
- 1
- Next